Blackstone Life Sciences invests $250 mln in Anthos Therapeutics

Blackstone Life Sciences said Feb. 27 that it launched Anthos Therapeutics Inc, a biopharmaceutical company focused on advancing targeted therapies for high-risk cardiovascular patients. Blackstone is investing $250 million in Anthos. Novartis will have a minority.

DealsNorth AmericaUSHealthcareBriefs